Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprotirome Monotherapy in Primary Hypercholesterolemia
NCT00776321Phase 2Completed
- Sponsor
- Karo Healthcare AB
- Start
- Sep 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eprotirome in hypercholesterolemia (3 arms), sponsored by Karo Healthcare AB. Primary endpoint: Low Density Lipoprotein Cholesterol at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
eprotirome
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00776321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00776321.